Author

Mercedes Martillo

Observed institution: Multiple Myeloma Research Foundation

ORCID: 0009-0009-3220-2997

Observed ORCID: 0009-0009-3220-2997

OpenAlex ID: A5079006969

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

2024 · Shambavi Richard, Alexander M. Lesokhin, et al. · Nature Cancer · 22

Abstract CT262: Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial

2023 · Hearn J. Cho, Shambavi Richard, et al. · Cancer Research · 4

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

2023 · Joshua Richter, Jeffrey A. Zonder, et al. · Blood · 3

PA-286 Longitudinal Single-Cell Profiling Reveals Reproducible Clonal Expansion of Cytotoxic CD8+ TEMRA Cells Following Daratumumab-Based Therapy

2026 · Chaitanya Acharya, Reyka Jayasinghe, et al. · Clinical Lymphoma Myeloma & Leukemia

Direct-to-patient research: Opportunity brings challenges

2025 · Anne Quinn-Young, Michael Andreini, et al. · Cancer Treatment and Research Communications

Works count: 5

Citation count: 29

H-index: 3

I10-index: 1